Stockscreener 앱 받기
28.00
1.70%
0.435
전일 마감가:
$27.56
열려 있는:
$26.77
하루 거래량:
184.98K
Relative Volume:
0.09
시가총액:
$2.58B
수익:
$490.73M
순이익/손실:
$-50.26M
주가수익비율:
-46.43
EPS:
-0.603
순현금흐름:
$-20.37M
1주 성능:
+1.11%
1개월 성능:
-5.69%
6개월 성능:
+10.78%
1년 성능:
+34.82%
1일 변동 폭
$26.77
$28.19
1주일 범위
$26.15
$28.29
52주 변동 폭
$12.91
$42.13
Travere Therapeutics Inc Stock (TVTX) Company Profile
명칭
Travere Therapeutics Inc
전화
888-969-7879
주소
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
28.00 | 2.54B | 490.73M | -50.26M | -20.37M | -0.603 |
VRTX
Vertex Pharmaceuticals Inc
|
455.09 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
757.00 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
695.48 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.39 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재개 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-21 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-12-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-20 | 개시 | Citigroup | Neutral |
| 2023-09-22 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 재개 | Evercore ISI | Outperform |
| 2023-07-21 | 개시 | JP Morgan | Overweight |
| 2023-06-07 | 재개 | Piper Sandler | Neutral |
| 2023-05-22 | 개시 | TD Cowen | Outperform |
| 2023-05-05 | 업그레이드 | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-21 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-12-14 | 개시 | Stifel | Hold |
| 2022-12-05 | 개시 | Wells Fargo | Overweight |
| 2022-09-21 | 개시 | Bryan Garnier | Sell |
| 2022-07-14 | 재개 | Canaccord Genuity | Buy |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-28 | 개시 | H.C. Wainwright | Buy |
| 2021-05-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Aug Spikes: Should value investors consider Travere Therapeutics Inc2026 Price Swings & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Travere Therapeutics price target lowered to $41 from $44 at JPMorgan - TipRanks
Earnings Risk: Is Cayson Acquisition Corp Equity Right stock a falling knife or bargain buy2026 Volatility Report & High Accuracy Swing Trade Signals - baoquankhu1.vn
FOMO Trade: Is Snail Inc forming bullish engulfing patternsMarket Trend Review & Weekly Top Gainers Trade List - baoquankhu1.vn
JPMorgan Chase & Co. Has Lowered Expectations for Travere Therapeutics (NASDAQ:TVTX) Stock Price - MarketBeat
JP Morgan Lowers Price Target for TVTX to $41.00, Maintains Over - GuruFocus
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Travere Therapeutics (TVTX) Gains Attention with Potential FDA A - GuruFocus
Citi opens ‘upside 90-day catalyst watch’ on Travere Therapeutics - TipRanks
Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts - MSN
Travere Therapeutics (TVTX) reports 144% annual growth in Filspari sales for 2025 - MSN
Responsive Playbooks and the TVTX Inflection - Stock Traders Daily
Travere Therapeutics, Inc. (TVTX) positioned for long-term growth in rare disease market - MSN
Highs Report: Can Travere Therapeutics Inc be recession proofShare Buyback & Growth Focused Investment Plans - baoquankhu1.vn
Is Travere Therapeutics (TVTX) Pricing Signal An Opportunity After Recent Share Price Pullback? - simplywall.st
TVTX SEC FilingsTravere Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Travere Therapeutics Inc SEC Filings - Stock Titan
TVTX Earnings History & Surprises | EPS & Revenue Results | TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) - ChartMill
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $280,900.00 in Stock - MarketBeat
Travere Therapeutics (TVTX) CLO exercises options and sells 10K shares - Stock Titan
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs - MSN
Cinctive Capital Management LP Makes New $2.26 Million Investment in Travere Therapeutics, Inc. $TVTX - MarketBeat
Earnings Recap: Is Travere Therapeutics Inc stock heavily shorted2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
166,000 Shares in Travere Therapeutics, Inc. $TVTX Purchased by Apis Capital Advisors LLC - MarketBeat
How Investors Are Reacting To Travere Therapeutics (TVTX) FILSPARI Momentum And Mirum Milestone Windfall - Sahm
Understanding the Setup: (TVTX) and Scalable Risk - Stock Traders Daily
How liquid is Travere Therapeutics Inc. stockProfit Target & Smart Investment Allocation Insights - mfd.ru
Piper Sandler Increases Target Price for Travere Therapeutics (TVTX) - Finviz
Assessing Travere Therapeutics (TVTX) Valuation After FILSPARI Sales Momentum And Expected Mirum Milestone Payment - Sahm
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Kentucky Teachers Retirement System Invests $732,000 in Travere Therapeutics - National Today
Travere Therapeutics, Inc. $TVTX Shares Sold by GW&K Investment Management LLC - MarketBeat
Published on: 2026-03-07 06:27:27 - baoquankhu1.vn
Royce & Associates Reduces Stake in Travere Therapeutics - National Today
Royce & Associates LP Reduces Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Vanguard Group Inc. Has $158.06 Million Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Exploring a 44.65% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Legato Capital Management LLC Acquires Shares of 71,030 Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
TVTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Total debt per share of Travere Therapeutics, Inc. – BOATS:TVTX - TradingView
Travere Therapeutics (TVTX) Is Up 7.4% After FILSPARI-Fueled Revenue Surge And Narrower LossesHas The Bull Case Changed? - simplywall.st
Travere Therapeutics, Inc. (TVTX) Stock Analysis: A 39% Upside Potential Sparks Investor Interest - DirectorsTalk Interviews
Travere Therapeutics (TVTX) CEO sells 60,000 shares in 10b5-1 trade - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM) - The Globe and Mail
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory - Finviz
Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 - Finviz
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics Inc (TVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Travere Therapeutics Inc 주식 (TVTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| REED ELIZABETH E | Chief Legal Officer and GC |
Mar 16 '26 |
Sale |
28.09 |
10,000 |
280,861 |
105,211 |
0.99%
3.03%
자본화:
|
볼륨(24시간):